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Background: Ceragenins, synthetic mimics of endogenous antibacterial peptides, are promising candidate antimicrobial
agents. However, in some settings their strong bactericidal activity is associated with toxicity towards host cells. To modulate
ceragenin CSA-13 antibacterial activity and biocompatibility, CSA-13-coated magnetic nanoparticles (MNP-CSA-13) were
synthesized. Transmission electron microscopy (TEM), Fourier transform infrared spectroscopy (FT-IR), differential scanning
calorimetry (DSC) and thermogravimetric analysis (TGA) were used to characterize MNP-CSA-13 physicochemical
properties. Bactericidal action and ability of these new compounds to prevent Pseudomonas. aeruginosa biofilm
formation were assessed using a bacteria killing assay and crystal violet staining, respectively. Release of hemoglobin from
human red blood cells was measured to evaluate MNP-CSA-13 hemolytic activity. In addition, we used surface activity
measurements to monitor CSA-13 release from the MNP shell. Zeta potentials of P. aeruginosa cells and MNP-CSA-13
were determined to assess the interactions between the bacteria and nanoparticles. Morphology of P. aeruginosa
subjected to MNP-CSA-13 treatment was evaluated using atomic force microscopy (AFM) to determine structural
changes indicative of bactericidal activity.
Results: Our studies revealed that the MNP-CSA-13 nanosystem is stable and may be used as a pH control system
to release CSA-13. MNP-CSA-13 exhibits strong antibacterial activity, and the ability to prevent bacteria biofilm formation
in different body fluids. Additionally, a significant decrease in CSA-13 hemolytic activity was observed when the
molecule was immobilized on the nanoparticle surface.
Conclusion: Our results demonstrate that CSA-13 retains bactericidal activity when immobilized on a MNP while
biocompatibility increases when CSA-13 is covalently attached to the nanoparticle.
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Ceragenin CSA-13 belongs to family of synthetic mimics
of cationic antimicrobial peptides (CAPs) that display
strong antibacterial activities [1,2]. Cationic lipids such
as CSA-13 are easier to prepare and purify than anti-
microbial peptides [3]. They are also resistant to diges-
tion by proteases that are commonly present at infection
sites [4]. Numerous reports describe CSA-13 activity
against multidrug-resistant bacteria, lipid-enveloped viruses
and parasites [3,5,6]. The mechanism of CSA-13 action in-
volves direct interaction with negatively charged bacterial
membrane molecules including lipopolysaccharide and* Correspondence: mikro.nano@umb.edu.pl
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permeabilization [7,8]. However, CSA-13′s ability to
compromise lipid organization in bacterial membranes
is not completely selective, and, at higher concentra-
tions, CSA-13 can affect the lipid organization within
host cell membranes, which in the case of RBCs leads to
hemolysis [7,8]. Methods intended to reduce potential
harmful effects of CSA-13 and other ceragenins are pro-
vided by nanotechnology strategies and the use of nano-
particles as drug delivery systems (DDS) [9,10]. Generally,
this approach may prove beneficial in providing a larger
therapeutic window (i.e., the difference in effective vs.
toxic concentrations). Among many types of nanoparti-
cles, magnetic nanoparticles (MNPs) are one of the most
promising materials in nanomedicine [11]. They can be
delivered to a specific area via a magnetic field [12-14].ess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
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limits and helps control drug toxicity. Additionally,
MNP surface functionalization provides the opportunity
to attach different active molecules such as drugs or
homing ligands and combine diagnostic and therapeutic
activities within the same structure [15]. In this study,
we developed a novel magnetic nanosystem made out of
an iron oxide core, aminosilane layer and CSA-13. Our
results suggest that immobilization of CSA-13 on the
MNP surface significantly reduces membrane toxicity
to RBCs and increases antimicrobial activity against
selected bacteria.
Results and discussion
The synthesis of MNP-CSA-13 and the surface modifica-
tion process is shown in Figure 1. The MNP magnetic core
was obtained following a modification of Massart’s method
[16]. After formation, magnetic nanoparticles were treated
with (3-aminopropyl)trimethoxysilane (APTMS) to linkFigure 1 Schematic representation of MNP-CSA-13 synthesis. The structures
(panel B). The overall surface modification procedures: In the first step bare MNP
MNPs were reacted with gluteraldehyde, a process resulting in the formation of
imine bond formation (panel C). Final structure of MNPs functionalized with CSAthe amino-terminated silica to their surface. Then amine
functionalized silica nanospheres were treated with glutar-
aldehyde, to obtain a platform for CSA-13 immobilization.
The terminal aldehyde groups from this surface are able to
react with the primary amine groups of CSA-13. This reac-
tion results in an imine bond between the surface and
CSA-13. We anticipate that amine group at the C3 position
in CSA-13 is the primary site of reactivity because it is less
sterically hindered than other amines in the molecule.
Imine formation for CSA-13 immobilization was selected
because treatment of imines with an excess of water leads
to their hydrolysis back to an aldehyde and an amine, espe-
cially in the presence of acid. During infection and inflam-
mation a decrease of the pH frequently occurs [17,18].
Therefore, MNP-CSA-13 could be used as carriers for con-
trolled antibiotic delivery to kill microorganisms at infec-
tion sites where the pH is usually less than 6 [19,20]. The
release of CSA-13 from MNP-CSA-13, subjected to a
magnetic field, was assessed by measuring the increase ofof ceragenin CSA-13 (panel A) and APTMS coated magnetic nanoparticles
s were coated with an aminosilane layer (APTMS), then aminosilane-coated
terminal aldehyde groups able to interact with ceragenin CSA-13 through
-13 (panel D).
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is altered (Figure 2). The release rate was expected to
depend on local pH, and over a one hour a much slower
release rate was observed at pH 7.4 (10% release) as com-
pared to pH 5 (25% release). We did not observe differ-
ences between intrinsic surface activity of CSA-13 at pH
7.4 and 5 (data not shown). We conclude that lower pH
accelerates imine bond hydrolysis, liberating CSA-13 from
the nanoparticle. It is worth noting that rapid CSA-13
release during the first 20 minutes is potentially due to a
burst effect [21]. The ability to control CSA-13 release
from nanoparticles in a low pH indicates a potential benefit
of using this nanosystem in eradication of Helicobacter
pylori. High susceptibility of H. pylori to CSA-13 was pre-
viously described [22]. Moreover, the observed burst effect
of CSA-13 release may be useful for certain applications,
especially for wound treatment, targeted delivery and
pulsatile release [23].
Figure 3A shows FT-IR spectra (A – C) for aminosilane-,
glutaraldehyde- and ceragenin-functionalized magnetic
nanoparticles (MNP@NH2; MNP@NH=CH(CH2)3CHO;
MNP-CSA-13 respectively). The curve D represented FT-IR
spectrum of unbound CSA-13. The existence of a magnetic
core in all samples is indicated by a band at ~550 cm−1,
which corresponds to the Fe-O stretching mode of Fe3O4.
The spectrum of MNP@NH2 shows a broad band at ~
1000–1090 cm−1 associated with Si-O, Si-O-Si and Fe-O-Si
stretching vibrations. In all samples, the bands around
1557 cm−1 and above 3300 cm−1 correspond to N-H bend-
ing and stretching vibrations, respectively. After functiona-
lization with glutaraldehyde the stretching vibration of theFigure 2 pH-dependent release of CSA-13 from MNP-CSA-13. CSA-13
release (hydrolysis of imine bond) was monitored by recording changes
of surface tension at an air-water interface of a MNP-CSA-13 suspension.
A rapid increase of CSA-13 release during the first 10 minutes after
placing MNP-CSA-13 in a low pH buffer (pH = 5) was observed (black
squares). After this time the shape of the curves indicates further gradual
release. On the other hand, at pH= 7.4, slow, but progressive release of
CSA-13 molecules from MNP-CSA-13 was observed (white circles). Data
represent mean ± SD from 3 experiments.C=O bond around 1654 cm−1 was recorded. CSA-13 at-
tachment to the MNP surface was detected by a band at
1738 cm−1, which corresponds to the imide stretching
band. Additionally, the imide in-plane stretching bands
were found at 1564 cm−1. The presence of C-H stretching
modes around 2930 cm−1 and 2850 cm−1 associated with
implemented ethyl and alkyl groups further confirm the
presence of a silica shell on the MNP surface and CSA-13
functionalization. The characteristic band for free CSA-13
was present within MNP-CSA-13, indicating that CSA-13
molecules were immobilized on the nanocomposite surface.
The thermal properties of MNP-CSA-13 were character-
ized by differential scanning calorimetry (DSC) (Figure 3B).
The heating curves of aminosilane- and glutaraldehyde-
and ceragenin-functionalized MNPs indicates differences
in the chemical nature of coating. At temperatures higher
than 150°C the breakdown of the organic skeleton (decom-
position of methoxyl and propylamine groups) was ob-
served in the DSC curve of MNP@NH2 (empty circles).
Analysis of the curves for glutaraldehyde functionalized
MNPs (gray squares) and CSA-coated MNP (black trian-
gles) indicate that these peaks can’t be distinguished,
which can be explained by the functionalization of the
aminosilane surface by glutaraldehyde and ceragenin re-
spectively. In the curve for glutaraldehyde- and CSA-13-
functionalized MNPs, a large endothermic transition was
found from 150 to 400°C. Additionally, a high endothermic
peak for MNP-CSA-13 at 235°C was observed. Figure 3
panels C and D show the thermogravimetric analysis re-
sults for the aminosilane-, glutaraldehyde-, and CSA-13-
functionalized magnetic nanoparticles, respectively. Bare
MNP shows 6% weight loss in the temperature range
50–800°C, which is directly associated with the removal
of adsorbed water and decomposition of hydroxyl sur-
face groups [24]. The thermogravimetric analysis curves
(Figure 3C) show that the weight loss for aminosilane-
and glutaraldehyde-coated MNPs during the performed
analysis is about 8%. Curve comparison of glutaralde-
hyde modified MNPs and aminosilane modified MNPs,
(Figure 3D), revealed a characteristic peak at 570°C.
After glutaraldehyde decomposition, the shape of both
curves did not differ. The thermogravimetric analysis of
CSA-13 functionalized MNPs (Figure 3C) showed a total
weight loss of 35%. The 14% weight loss of the MNP-
CSA-13 (compared to the weight loss of bare and
MNP@NH2) indicated successful CSA-13 immobilization
on the MNP surface, with ~ 14% CSA-13 content. For
MNP-CSA-13, we observed two decomposition peaks,
with the first at 240°C and the second at 400°C (Figure 3D).
A second peak indicated decomposition of the aminosi-
lane layer, which was recorded for all analyzed samples.
Based on weight lost and total amount of amine group on
the MNP surface, we calculated that the number of CSA-
13 molecules was 3.53 × 1013, which corresponds to a
Figure 3 Physicochemical properties of synthesized magnetic nanoparticles. ATR FT-IR spectra of the aminosilane- (curve A), glutaraldehyde - (curve B),
CSA-13 (curve C) functionalized MNPs and free CSA-13 (curve D) (panel A). Panels B-D show thermal properties of aminosilane- (light gray circle line),
glutaraldehyde - (square gray line) and CSA-13 (triangle black line) functionalized MNPs. Differential scanning calorymetry analysis curves, thermogravimetric
analysis curves and differential thermal analysis represent panels B, C and D respectively. Data from one experiment performed in triplicate are shown.
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in the original volume of CSA-13 solution used for MNP
functionalization.
A relatively narrow size distribution of magnetic nano-
particles functionalized with CSA-13 is shown in Figure 4.
Particles were spherical with a diameter as determined
from the TEM image of 14 nm± 2 nm (the size was calcu-
lated using 100 randomly selected particles). Nanoparticles
should be well separated due to the repulsion between
CSA-13 molecules in the coating layer, but the observed
MNPs clusters can be explained by the drying process inFigure 4 Transmission electron microscopy (TEM) images of MNP-CSA-13.
(panel B) of MNP-CSA-13. Ceragenin-loaded magnetic nanoparticles had an ir
MNP size increase. Data from one experiment performed in triplicate are showthe preparation for TEM measurements. When compared
to previously characterized amino- functionalized MNPs,
the size of CSA-13 functionalized MNPs did not signifi-
cantly differ [25]. Additionally, the accuracy of TEM size
analysis was in agreement with XRD analysis (data not
shown) [25].
P. aeruginosa is an opportunistic pathogen that fre-
quently causes hospital infection, affecting mostly im-
munocompromised patients and those suffering from
cystic fibrosis [26,27]. Using physicochemical evaluation,
the total amount of CSA-13 on the MNPs surface wasTransmission electron microscopy images (pane A) and size distribution
on oxide core of 9 ± 2 nm. MNP functionalization with CSA-13 results in a
n.
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concentration (free CSA-13 and CSA-13 attached to
MNPs) per ml were compared. Figure 5A shows that
immobilization of CSA-13 on the nanoparticle surface
did not affected its antibacterial activity against P. aeru-
ginosa, and this observation is in agreement with a pre-
vious study where CSA-13 in combination with pluronic
acid was tested [28]. Bactericidal activity against clinical
isolates of P. aeruginosa strains shows that more than
60% of bacteria were killed using a 1 μg/ml dose, and at
concentration of 10 μg/ml no bacteria growth was ob-
served (Figure 5C). Interestingly, a dose-dependent de-
crease of bacteria growth was observed for uncoated
MNPs, with a 80% decrease at 100 μg/ml. The decline of
P. aeruginosa Xen 5 chemiluminescence after treatment
with MNP-CSA-13 is shown in Figure 5D. Comparison of
bacteria luminescence after MNP-CSA-13 addition sug-
gests that the nanocomposite is more efficient in killing
bacteria than CSA-13 alone. The decrease of chemilumin-
escence, which indicates the ability of MNP-CSA-13 to
affect bacteria metabolism, reached up to 70%, as com-
pared to colistin (~24%), and unfunctionalized MNPs
(~40%). These data support the hypothesis that a synergis-
tic effect of MNPs and CSA-13 might exist. Novel formu-
lations using lipids and polymeric nanostructures forFigure 5 Bactericidal activity of MNP@CSA-13 against P. aeruginosa strains. Bac
(5 μg/ml) against P. aeruginosa PAO14 (CT - control) (panel A). To compare anti
CSA-13 concentration was estimated based on physicochemical data and yield
P aeruginosa isolated from cystic fibrosis sputum in the presence of MNPs (bla
aeruginosa Xen 5 (white triangels) chemiluminescence signal (~108 CFU/ml) afte
CSA-13 (100 μg/ml; black circles) and MNP-CSA-13 (100 μg/ml; white circle
significance compared to untreated bacteria cells (p≤ 0.05); ^ statistical signifdelivery of antimicrobial agents may be useful in other ap-
plications as well [29]. A magnetic drug delivery system
was previously proposed for antibiotics such as chloram-
phenicol (successfully loaded into OA/SDS-coated MNPs)
[30], nystatin [31] and streptomycin [24], both loaded on
chitosan coated MNPs; however, the attaching process
was achieved by chemical adsorption, based on non-
specific electrostatic or hydrophobic interactions. The co-
valent immobilization of antibiotics proposed here pos-
sesses some advantages compared to chemical adsorption.
Recent reports show that immobilization of antimicrobial
peptides (AMPs) onto a biomaterial surface helps to avoid
AMP limitations, such as short half-life and toxicity asso-
ciated with higher concentrations of soluble peptides [32].
Additionally, Zhao et al. argued that advantages of attach-
ment by chemical reaction also include low incidence of
side effects and non-accumulation in tissues (brain, liver
and spleen) [33]. Moreover, covalent bonding allows the
pH-depending control of substance release, due to the
mechanism of the hydrolysis reaction [34].
Bacteria growth in biofilm form is associated with in-
creased resistance to antibiotic treatment. Additionally,
biofilm plays a key role in chronic Pseudomonas infec-
tions [35-37]. Therefore, new approaches to prevent bio-
film formation are of great interest. As indicated intericidal activity of CSA-13 (0.7 μg/ml), MNPs (4.3 μg/ml) and MNP-CSA-13
bacterial potential of MNP, CSA-13 and MNP-CSA-13 against P. aeruginosa,
of reaction. Panels B and C show survival of PAO1 and a clinical strain of
ck circles) and MNP-CSA-13 (white circles) respectively. Reduction of P.
r colistin – COL (100 μg/ml; white square), MNP (100 μg/ml; black square),
s) addition – panel D. Data represent mean ± SD, n = 3 with * statistical
icance compared to bacteria treated with free CSA-13 (p≤ 0.2) (panel A).
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tion and effectively kill bacteria embedded into the biofilm
matrix. At MNP-CSA-13 concentration of 1 μg/ml, bio-
film formation decreased by ~ 40%. Total reduction of ad-
hesion of P. aeruginosa on a polystyrene surface was
observed at a concentration of 100 μg/ml. A similar effect
was obtained for both tested P. aeruginosa strains (PAO1
and a selected clinical strain). Collected results are
strongly supported by a recent study showing that CSA-
13 is active against bacteria forming biofilms. Previous re-
ports indicate that more than 50% of bacteria cells in such
networks were killed at 50 μg/ml. Total reduction of live
bacteria cells was observed with the concentration of
100 μg/ml [38]. Additionally, another study shown that
CSA-13 inhibits the adhesion of P. aeruginosa to an abi-
otic surface and reduces biofilm mass [39]. Our results in-
dicate that MNP-CSA-13 is useful in preventing bacteria
biofilm formation, and it may have higher activity than
previously described nanosystems [40]. Iron oxide nano-
particles coated by a carboxylate shell at a concentration
of 1000 μg/ml were able to kill up to 33% of S. aureus after
initial biofilm formation over a 24 hour time period [40].
Similarly, another study demonstrated significant reduc-
tion in biofilm growth for S. aureus and P. aeruginosa in
the presence of iron oxide and gold nanoparticles at a
concentration range 50–150 μg/ml [41]. Hetric et al. re-
vealed that nitric-oxide releasing silica nanoparticles
strongly inhibit biofilm formation by Gram-negative and
Gram-positive bacteria [42]. Abdelghany et al. showed
that gentamycin-loaded polylactide-co-glycolide nanopar-
ticles possess excellent potential against a pre-formed P.
aeruginosa biofilm [43].
The toxicity attributed to AMPs is frequently correlated
to high concentrations used to compensate for their
relatively short half-life due to rapid protease digestion or
aggregate formation [44,45]. Ceragenins, including CSA-
13, are likely cause red blood cell (RBC) hemolysis at high
concentrations as a consequence of their membrane activ-
ity. This effect is caused by membrane destruction afterFigure 6 MNP-CSA-13 activity against bacteria biofilm formation. Bactericidal
biofilm forming P. aeruginosa PA01 (panel A) and P. aeruginosa clinical strain (
in biofilm. Results represent mean ± SD obtained from 3 experiments. * statistiinsertion [46,47]. An understanding of the mechanisms
governing magnetic nanoparticle interactions with RBC
membranes is necessary to create an optimal nanosystem
for medicinal applications [48]. Data in Figure 7A indicate
that MNP-CSA-13 did not affect RBC membrane perme-
ability at a concentration range of 1 – 100 μg/ml. This
concentration range of the nanoparticles effectively kills
planktonic P. aeruginosa as well as the bacteria in a ma-
ture biofilms. This result suggests that attachment of
CSA-13 to the MNP surface can be used to control CSA-
13 toxicity and potentially toxicity of other cationic lipids
using covalent immobilization on the nanoparticle surface.
Recent data show that CSA-124 (thiolated derivative of
CSA-13) binding to silver nanoparticles (SNP) via non-
specific interactions (thermodynamically favorable silver-
sulfur bonding) caused 100 percent hemolysis at a con-
centration of 50 μg/ml, which is 1.5 times higher com-
pared to CSA-124 alone [49]. Our study indicates that
CSA-13, at these same concentrations, covalently attached
to MNPs caused ~1% hemolysis. These data provide evi-
dence that chemical adsorption of drugs onto nanoparticle
surfaces decreases hemolysis. Thus, we show the advan-
tage of covalent binding compared with non-specific
chemical adsorption. Ruden et al. reported that increasing
the concentration of silver ions in combination with vari-
ous antimicrobial peptides enhanced antibacterial activity.
However, the combination of those peptides with silver
nanoparticles did not increase hemolysis [50]. Another
study indicated that RBCs exposed to gold coated mag-
netic nanoparticles induces hemolysis rates of under 5%
[51]. Similarly, encapsulation of daunorubicin on self-
assembled iron oxide magnetic nanoparticles presented
good hemocompatibility, with a hemolysis rate less than
5% [52]. Thus, stable immobilization of drugs, including
synthetic analogs of antimicrobial peptides, onto a nano-
material could be a method to overcome their limitations
and side effects. Considering recent data that indicate
some limitation for ceragenin use in systemic application
[28], the antibacterial effect of MNP-CSA-13 was assessedactivity of MNPs (black circles) and MNP-CSA-13 (white circles) against
panel B). Panels A and B represent effective killing of bacteria embedded
cal significance compared to bacteria treated with unfunctionalized MNPs.
Figure 7 Biocompatibility and antibacterial activity of MNP-CSA-13 in different body fluids. Hemoglobin release from human red blood cells (RBCs) after
CSA-13 (white squares), MNP (white circles) and MNP-CSA-13 (black circles) addition (panel A). Antibacterial activity of MNP-CSA-13 against Pseudomonas
aeruginosa Xen 5 in different human body fluids assessed using chemiluminescence measurement (panel B). In each condition the white column indicates
luminescence of control samples. The black column indicates the luminescence signal after free ceragenin CSA-13 (100 μg/ml) treatment. The gray column
indicates luminescence signal after addition of MNPs (100 μg/ml). Light gray column show luminescence signal after addition of MNP-CSA-13. Results
represent mean ± SD, n = 3; * statistical significance compared to untreated control, ^ compared to bacteria treated with CSA-13 (p≤ 0.05).
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taining 50% of different body fluids (Figure 7B). A signifi-
cant decrease of bacterial luminescence was observed
after addition of CSA-13, MNP and MNP@CSA-13 to
cerebrospinal fluid, abdominal fluid and blood plasma
specimens. Moreover, we observed that MNP-CSA-13 ac-
tivity was higher than activity of CSA-13. It was also noted
that free and functionalized CSA-13 possess the ability to
bind bacterial membranes. Rapid interaction between P.
aeruginosa cells and CSA-13 labeled with a fluorescent
probe - BODIPY-succinimidyl ester (CSA-119) was re-
cently reported. This study underlines the high affinity
that positively charged ceragenins have for negatively
charged bacterial membranes [39]. In agreement with re-
ported results, we observed that ceragenin functionalizedFigure 8 P. aeruginosa cell disruption under MNP-CSA-13 treatment, evalu
after CSA-13 (B), MNP (C) and MNP-CSA-13 (D) addition. Analysis of cell surfa
the intracellular contents.MNPs possess positive zeta potential (+39 eV) promoting
the interaction with bacterial membrane surface charac-
terized by negative zeta potential (−15 eV). Additionally
after MNP@CSA-13 addition to bacteria suspension, a
change of zeta potential from −15 eV to −6 eV was ob-
served. In agreement with our results, Thill et al. revealed
that cationic charged nanoparticles interact with nega-
tively charged bacterial membranes via electrostatic inter-
action [53].
To confirm the antibacterial activity of ceragenin func-
tionalized magnetic nanoparticles we utilized atomic
force microscopy (AFM) to identify changes in cell
morphology and mechanical properties of P. aeruginosa
upon MNP-CSA-13 treatment (Figure 8). The results in-
dicate that MNP-CSA-13 adhered to bacteria and thenated using atomic force microscopy. Images recorded before (A) and
ce topography showed increasing membrane roughness and leakage of
Niemirowicz et al. Journal of Nanobiotechnology  (2015) 13:32 Page 8 of 11disrupted the cell membrane with leakage of the intra-
cellular contents. Addition of unfunctionalized MNPs
changes the bacterial shape and induce bacteria aggrega-
tion. Similarly to our finding De et al. revealed increases
in membrane premeability of P. aeruginosa cells after
treatment with lanthanium calcium manganate nanopar-
ticles [54]. Disorganization of Gram-negative bacteria
membranes was also confirmed for zinc oxide nanoparti-
cles [55]. Additionally, our previous report indicates that
magnetic nanoparticles possess the ability to aggregate
P. aeruginosa cells due to interaction with their cell-wall
component [25]. Combining CSA-13 antibacterial poten-
tial with the magnetic properties of MNP may have
prospects for in vivo applications as a contrast in mag-
netic resonance imagining and novel tool to monitor in-
fection sites in real-time. In a recent study the use of
MNP in magnetic resonance imaging was explored [2],
and compared to the MNP in the study the nanosystem
presented in this work shows higher stability due to co-
valent CSA immobilization and possibility of controlled
release of CSA-13, depending on the environmental pH
[2]. However, the potential as a contrast agent needs to
be explored in further studies.Conclusion
Presented results suggest a promising future for the use of
nanoparticles functionalized by antimicrobial cationic lipids
in biomedical applications as drug carriers in a controlled
drug delivery system. The MNP-CSA-13 nanoparticles
demonstrate dual benefits: a decrease of ceragenin
hemolytic activity and increase of antimicrobial properties
in body fluids. Furthermore, these functionalized MNPs
demonstrate the utility of a platform for creating a multi-
task nanosystem, which can be useful in theranostic
applications.Methods
Synthesis of magnetic nanoparticles functionalized by
CSA-13 (MNP-CSA-13)
Iron oxide magnetic nanoparticles (MNP) were synthe-
sized via modification of Massart’s methods [16]. The
shell around the magnetic core was obtained via poly-
condensation of 3-aminopropylotrimethoxy silane, then
the nanoparticles were suspended in ethanol and glutar-
aldehyde was added. After 60 minutes of stirring at
room temperature, the precipitate was isolated by mag-
netic decantation. The collected precipitate was washed
with ethanol. In the final step, MNPs functionalized by
glutaraldehyde were re-suspended in ethanol containing
CSA-13 and sonicated for 1 h. The precipitate was iso-
lated by an external magnetic field, then washed three
times with ethanol, three times with PBS and dried to
powder at 60°C.Nanoparticle characterization
FT-IR spectra were recorded using a Thermo Scientific
Nicolet 6700 FT-IR spectrophotometer. A thin layer of
sample was placed in direct contact with an infrared atten-
uated total reflection (ATR) diamond crystal. All FT-IR
spectra were collected in the wavenumber range of 4000 to
500 cm−1 by co-adding 32 scans with a resolution of 4 cm
−1. Differential scanning calorimetry (DSC) was performed
on a Mettler Toledo Star DSC system. Nitrogen was used
as a purge gas (10 ml·min−1). Samples between 2 and
5 mg were placed in aluminum pans and heated from 25
to 450°C with a heating rate of 20°C/min. Thermogravi-
metric analysis (TGA) was recorded using a Mettler To-
ledo Star TGA/DSC unit. Nanoparticles (1–2 mg) were
placed in the aluminum pans (40 μl) and heated from 50
to 800°C with a heating rate of 10°C/min. The morphology
of MNPs was studied with transmission electron micros-
copy TEM/EDX (Tecnai G2 X-TWIN). A drop of the
nanoparticle dispersion in THF was deposited onto a
carbon-coated copper grid and dried in a vacuum oven at
temperature 50°C.
Quantitative analysis of CSA-13′s presence on MNP
surface
As shown previously, the total number of amine groups
present at the MNP surface in the MNPs@NH2 sample,
determined by acid–base titration, was 0.42 mmol g−1
[56]. The total amount of CSA-13 on the MNPs was es-
timated based on weight loss during TGA analysis.
Release of ceragenin from MNP-CSA-13
In order to determine the percentage of CSA-13 release
in an in vitro setting, 10 μl of MNP-CSA-13 nanoparti-
cles (10 mg/ml) were suspended into 10 ml of PBS
(140 mM NaCl, 7.5 mM Na2HPO4; pH ~ 7.4) at pH = 7.4
and 5 respectively. In both environments, the cumulative
amount of ceragenin released into the solution was mea-
sured by surface tension at different time intervals using
the du Noűy ring method [57]. The surface tension was
calculated from the radius of the ring and the tear-off
force [57].
Measure of the zeta potential of Pseudomonas aeruginosa
cells and MNP-CSA-13
The zeta potential measurements on P. aeruginosa were
taken at 25°C on a Zetasizer Nano ZS (Malvern Instru-
ments, UK) apparatus, which is based on electrophoretic
light scattering. Attenuation selection, voltage selection
and measurement duration were set as automatic. The
quality of the measurements was evaluated by inspection
of the phase plot. Overnight cultures of bacteria were ad-
justed to 0.1 absorbance (600 nm) in PBS buffer (pH = 7.0).
MNP-CSA-13 was dispersed in PBS buffer at concentra-
tion 2.5 mg/ml. The assay was performed three times.
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To compare the bactericidal activities of CSA-13
(0.7 μg/ml) and MNP-CSA-13 (5 μg/ml) and MNPs
themselves (4.3 μg/ml) against P. aeruginosa PAO14,
killing assay/CFU counting method was performed [58].
The concentrations of tested agents were calculated to
added equal amount of free CSA-13 and CSA-13 mole-
cules attached to the MNP surface. Briefly, P. aeruginosa
was grown to mid-log phase at 37°C, re-suspended in
PBS, and brought to 108 CFU/ml (with the assumption
that an optical density at 600 nm of 0.35 corresponds to
108 CFU/ml). They were then diluted in PBS containing
different concentrations of CSA-13, MNPs or MNP-
CSA-13. After 1 h of incubation at 37°C the plates were
transferred to ice and suspensions were diluted 10- to
1000-fold in PBS. Then, 10 μl aliquots were spotted on
cetrimide-containing agar plates for overnight culture at
37°C, then CFUs were determined. In other set of ex-
periment changes of chemiluminescence intensity of P.
aeruginosa Xen5 after treatment with COL – colistin,
CSA-13, MNP and MNP-CSA-13 measurements were de-
termined as an additional method to assess bacteria viabil-
ity. Chemiluminescence was evaluated using Labsystems
Varioscan Flash (Thermo Scientific).
MNP-CSA-13 activity against bacteria biofilm formation
A biofilm of P. aeruginosa was grown for 48 h at 37°C
with and without the antibacterial agents. Each well was
washed four times with deionized water to remove
planktonic bacteria. Biofilm mass was evaluated using
crystal violet (CV) staining (0.1%). Excess stain was
rinsed off with deionized water and plates were dried.
Then, 100 μl ethanol was added and optical density
(OD) was determined at a wavelength of 570 nm. These
OD values were considered as an index of bacteria ad-
hering to the surface and forming a biofilm.
Hemolytic activity
MNPs, CSA-13 and MNP-CSA-13 hemolytic activity was
tested using human red blood cells (RBCs) suspended in
phosphate-buffered saline (PBS) (hematocrit ~5%) with a
concentration of tested antibacterial agents ranging from
0–100 μg/ml. RBCs were incubated with tested agents for
1 h at 37°C. Relative hemoglobin concentration in super-
natants after centrifugation at 2500 g was monitored by
measuring optical absorbance at 540 nm. 100% hemolysis
was taken from samples in which 1% Triton X-100 was
added to disrupt all cell membrane.
Antimicrobial activity of MNP-CSA-13 in different body
fluids
To assess the ability of MNP, MNP-CSA-13 and free CSA-
13 to kill bacteria in different compartments of the human
body, changes of P. aeruginosa Xen 5 chemiluminescence(~ 109 CFU/ml) in PBS mixed with 50% human blood
plasma, serum, cerebrospinal fluid, peritoneal fluid, saliva
and urine were assessed [28]. The luminomeric curves were
recorded during 30 minutes after its addition.
AFM imagining
AFM images were taken using an AFM BioScope Catalyst
(LABSOFT, Bruker Nano Surfaces Division, Santa Barbara,
USA). All measurements were performed in air-dried
samples. The data was processed using NanoScope® AFM
software.
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